Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 43Neoplasm Metastasis 5Neoplasms 4Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Non-Small-Cell Lung 3Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Cancer Metastatic 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Lymphoma, Non-Hodgkin 1Hyperglycemia 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1Carcinosarcoma 1Carcinoma, Lobular 1Breast Neoplasms, Male 1Anatomic Stage IV Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 5Gemcitabine 4Albumin-Bound Paclitaxel 4Trastuzumab 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3pazopanib 2Taxes 2Sorafenib 2Radiotherapy 2Radiation 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Doxorubicin 2Docetaxel 2Capecitabine 2romidepsin 1rV-Tricom 1peginterferon alfa-2a 1pegfilgrastim 1oblimersen 1methyl N-acetylsibirosaminide 1ixabepilone 1fludarabine phosphate 1fludarabine 1exemestane 1cediranib 1alvocidib 1Zoledronic Acid 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms, Male × Fulvestrant × Clear all
NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

OHSU Knight Cancer Institute

Phase 2 Terminated
12 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡